Dynavax Technologies Q2 2024 GAAP EPS $0.08 Beats $0.06 Estimate, Sales $73.795M Miss $76.102M Estimate
Portfolio Pulse from Benzinga Newsdesk
Dynavax Technologies (NASDAQ:DVAX) reported Q2 2024 GAAP EPS of $0.08, beating the $0.06 estimate, but sales of $73.795M missed the $76.102M estimate. EPS increased by 166.67% YoY, while sales grew by 22.48% YoY.
August 06, 2024 | 8:19 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Dynavax Technologies reported Q2 2024 GAAP EPS of $0.08, beating the $0.06 estimate, but sales of $73.795M missed the $76.102M estimate. EPS increased by 166.67% YoY, while sales grew by 22.48% YoY.
The positive EPS surprise and significant YoY growth in earnings are likely to have a positive short-term impact on DVAX's stock price. However, the sales miss may temper the enthusiasm, leading to a moderate positive impact overall.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100